Poly-substance use and antisocial personality traits at admission predict cumulative retention in a buprenorphine programme with mandatory work and high compliance profile

BMC Psychiatry

Per Tätting³  Mats Fridell²  Morten Hesse⁴  Leif Öhlin¹ 

[1] Department of Psychiatry, St Lars Hospital, Lund, Swedena;Professor, Department of Psychology, Lund University & Linnaeus University, Växjö, Sweden;Department of Psychiatry, St Lars Hospital, Lund, Sweden;Center for Alcohol and Drug Research, University of Aarhus, Copenhagen, Denmark

关键词: poly-substance;    antisocial personality disorder;    predictors;    compliance;    mandatory work;    Buprenorphine;   

Others  :  1124555
DOI  :  10.1186/1471-244X-11-81

 received in 2010-10-01, accepted in 2011-05-12,  发布年份 2011

【 摘 要 】

Background

Continuous abstinence and retention in treatment for alcohol and drug use disorders are central challenges for the treatment providers. The literature has failed to show consistent, strong predictors of retention. Predictors and treatment structure may differ across treatment modalities. In this study the structure was reinforced by the addition of supervised urine samples three times a week and mandatory daily work/structured education activities as a prerequisite of inclusion in the program.

Methods

Of 128 patients consecutively admitted to buprenorphine maintenance treatment five patients dropped out within the first week. Of the remaining 123 demographic data and psychiatric assessment were used to predict involuntary discharge from treatment and corresponding cumulative abstinence probability. All subjects were administered the Structured Clinical Interview for DSM-IV-TR, and the Symptom Checklist 90 (SCL-90), the Alcohol Use Disorder Identification Test (AUDIT), the Swedish universities Scales of Personality (SSP) and the Sense of Coherence Scale (SOC), all self-report measures. Some measures were repeated every third month in addition to interviews.

Results

Of 123 patients admitted, 86 (70%) remained in treatment after six months and 61 (50%) remained in treatment after 12 months. Of those discharged involuntarily, 34/62 individuals were readmitted after a suspension period of three months. Younger age at intake, poly-substance abuse at intake (number of drugs in urine), and number of conduct disorder criteria on the SCID Screen were independently associated with an increased risk of involuntary discharge. There were no significant differences between dropouts and completers on SCL-90, SSP, SOC or AUDIT.

Conclusion

Of the patients admitted to the programme 50% stayed for the first 12 months with continuous abstinence and daily work. Poly-substance use before intake into treatment, high levels of conduct disorder on SCID screen and younger age at intake had a negative impact on retention and abstinence.

【 授权许可】

   
2011 Öhlin et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 3.

【 参考文献 】

• [1]Kunoe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Kristensen O, Wall H: Retention in naltrexone implant treatment for opioid dependence. Drug and Alcohol Dependence 2010, 111:166-169.
• [2]Hunt WA, Barnett LW, Branch LG: Relapse rates in addiction programs. Journal of Clinical Psychology 1971, 27:455-456.
• [3]Kenne DR, Boros AP, Fischbein RL: Characteristics of opiate users leaving detoxification treatment against medical advice. Journal of Addictive Diseases 2010, 29:383-394.
• [4]Scherbaum N, Specka M: Factors influencing the course of opiate addiction. International Journal of Methods in Psychiatric Research 2008, 17(Suppl 1):S39-44.
• [5]Brewer DD, Catalano RF, Haggerty K, Gainey RR, Fleming CB: A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 1998, 93:73-92.
• [6]Ahmadi J, Kampman KM, Oslin DM, Pettinati HM, Dackis C, Sparkman T: Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment. American Journal on Addictions 2009, 18:81-86.
• [7]Ambrose-Lanci LM, Sterling RC, Weinstein SP, Van Bockstaele EJ: The influence of intake urinalysis, psychopathology measures, and menstrual cycle phase on treatment compliance. American Journal on Addictions 2009, 18:167-172.
• [8]Olsson M: DSM diagnosis of conduct disorder (CD) - A review. Nord J Psychiatry 2009, 63:102-112.
• [9]Hesse M, Pedersen MU: Antisocial personality disorder and retention: a systematic review. Therapeutic Communities 2007, 27:495-504.
• [10]Daughters SB, Stipelman BA, Sargeant MN, Schuster R, Bornovalova MA, Lejuez CW: The interactive effects of antisocial personality disorder and court-mandated status on substance abuse treatment dropout. Journal of Substance Abuse Treatment 2008, 34:157-164.
• [11]Berglund M, Thelander S, Jonsson E: Treatment of Alcohol and Drug Abuse. An Evidence-Based Review. Wiley-VCH Verlag, Weinheim; 2003.
• [12]Eriksson M, Lindstom B: Validity of Antonovsky's sense of coherence scale: a systematic review. Journal of Epidemiology and Community Health 2005, 59(6):460-6.
• [13]Berg JE, Brevik JI: Complaints that predict drop-out from a detoxification and counselling unit. Addictive Behaviors 1998, 23(1):35-40.
• [14]Feigin R, Sapir Y: The relationship between sense of coherence and attribution of responsibility for problems and their solutions and cessation of substance abuse over time. Journal of Psychoactive Drugs 2005, 37(1):63-73.
• [15]Fridell M, Hesse M: Psychiatric severity and mortality in substance abusers: a 15- year follow-up of drug users. Addict Behav 2006, 31(4):559-65.
• [16]Berg JE, Andersen S: Mortality 5 Years after Detoxification and Counseling as Indicatd by Psychometric Tests. Substance Abuse 2001, 22(1):1-10.
• [17]The National Board of Health and Welfare: Swedish National Guidelines for Treatment of Substance Abuse and Dependence. Stockholm. The National Board of Health and Welfare; 2007.
• [18]SOSFS 2009:27 (M): Medication-assisted treatment for opiate dependence. Stockholm. The National Board of Health and Welfare; 2009.
• [19]Lehrer M: The role of gas chromatography/mass spectrometry. Instrumental techniques in forensic urine drug testing. Clinics in laboratory medicine 1998, 18:631-649.
• [20]First M, Spitzer R, Gibbon M, Williams J: The Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II). I: description. Journal of Personality Disorder 1995, 9:83-91.
• [21]Arntz A: Do personality disorders exist? On the validity of the concept and its cognitive-behavioral formulation and treatment. Behaviour Research and Therapy 1999, 37S:97-134.
• [22]Ball SA, Rounsaville BJ, Tennen H, Kranzler HR: Reliability of personality disorder symptoms and personality traits in substance-dependent inpatients. Journal of Abnormal Psychology 2001, 110:341-352.
• [23]Derogatis LR, Lipman RS, Covi L: SCL-90: an outpatient psychiatric rating scale--preliminary report. Psychopharmacology Bulletin 1973, 9:13-28.
• [24]Fridell M, Cesarec Z, Johansson M, Thorson SM: Swedish Norms, Standardization and Validation of the Symptom Checklist 90 (Svensk Normering, Standardisering och Validering av Symptomskalan SCL-90. Stockholm: SIS; 2002.
• [25]Hansson K, Olsson M: Sense of coherence - a human endeavor (Känsla av sammanhang - ett mänskligt strävande). Nordic psychology 2001, 52:238-255.
• [26]Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M: Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption II. Addiction 1993, 88:791-804.
• [27]Bergman H, Källmen H: Alcohol use among Swedes and a psychometric evaluation of the alcohol use disorders identification test. Alcohol & Alcoholism 2002, 37:245-251.
• [28]Gustavsson JP, Bergman H, Edman G, Ekselius L, von Knorring L, Linder L: Swedish universities Scales of Personality (SSP): construction, internal consistency and normative data. Acta Psych Scand 2000, 102:217-225.
• [29]Angst J, Gamma A, Gastpar M, Lepine JP, Mendlewicz J, Tylee A: Gender differences in depression. Epidemiological findings from the European DEPRES I and II studies. European Archives of Psychiatry and Clinical Neuroscience 2002, 252:201-209.
• [30]Yang M, Coid J: Gender differences in psychiatric morbidity and violent behaviour among a household population in Great Britain. Social Psychiatry and Psychiatric Epidemiology 2007, 42:599-605.
• [31]Blonigen DM: Explaining the relationship between age and crime: contributions from the developmental literature on personality. Clinical Psychology Review 2010, 30:89-100.
• [32]Krueger RF, Markon KE, Patrick CJ, Iacono WG: Externalizing Psychopathology in Adulthood: A Dimensional-Spectrum Conceptualization and Its Implications for DSM-V. Journal of Abnormal Psychology 2005, 114:537-550.
• [33]Krueger RF: Continuity of axes I and II: toward a unified model of personality, personality disorders, and clinical disorders. Journal of Personality Disorder 2005, 19:233-261.
• [34]Walters GD, Brinkley CA, Magaletta PR, Diamond PM: Taxometric analysis of the Levenson Self-Report Psychopathy scale. Journal of Personality Assessment 2008, 90:491-498.
• [35]Fudala P, Bridge P, Williford W, Chiang N, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith J, Ling W, Malkerneker U, McNicholos L, Renner J, Stine S, Tusel D: Office-based Tretament of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone. New England Journal of Medicine 2003, 349:949-58.
• [36]Kakko J, Dybrandt Svanberg K, Kreek MJ, Helig M: 1-Year retention and social function after buprenorphine-assisted relapse prevention for heroin dependence in Sweden: a randomiserad, placebo-controlled trial. Lancet 2003, 361:662-68.
• [37]Simpson DD: Introduction to 5-year follow-up treatment outcome studies. Journal of Substance Abuse Teatment 2003, 25:123-12.
• [38]Siqueland L, Crits-Christoph P, Frank A, Daley D, Weiss R, Chittams J, Blaine J, Luborsky L: Predictors of dropout from psychosocial treatment of cocaine dependence. Drug and Alcohol Dependence 1998, 52:1-13.
• [39]Neufeld KJ, Kidorf MS, Kolodner K, King VL, Clark M, Brooner RK: A behavioral treatment for opioid-dependent patients with antisocial personality. Journal of Substance Abuse Treatment 2008, 34:101-111.
• [40]Bell MD: Three therapeutic communities for drug abusers: Differences in treatment environments. Int J Addictions 1985, 20:1523-1531.
• [41]Meier PS, Barrowclough C: Mental health problems: Are they or are they not a risk factor for dropout from drug treatment? A systematic review of the evidence. Drugs: education, prevention and policy 2009, 16:7-38.